Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CellCutis is a topical cosmetic anti-aging product developed by StemCutis, a dermatology-focused biotech company. The product utilizes a proprietary platform of ischemia-tolerant mesenchymal stem cell (itMSC)-derived growth factors and conditioned media, licensed from Stemedica. Unlike live cell therapies, CellCutis delivers a complex secretome—a mixture of regenerative proteins, cytokines, and growth factors—secreted by stem cells grown under low-oxygen conditions. This ischemia-tolerant technology is designed to enhance the concentration of factors that promote cellular regeneration, collagen production, and tissue repair. Applied topically, CellCutis is intended to improve skin appearance, reduce the visibility of wrinkles, and support overall skin rejuvenation. While marketed as a cosmetic product, the underlying itMSC platform has also been explored for clinical indications such as cutaneous photoaging and hair restoration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CellCutis.